KRAS and BRAF mutation detection: Is immunohistochemistry a possible alternative to molecular biology in colorectal cancer?

Gastroenterology Research and Practice

Volumn 2015, Issue , 2015, Pages

  Piton, Nicolas ^a   Borrini, Francesco ^b   Bolognese, Antonio ^b   Lamy, Aude ^a   Sabourin, Jean Christophe ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84929377486     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2015/753903     Document Type: Article

References (32)

1. J. Weitz, M. Koch, J. Debus, T. Höhler, P. R. Galle, and M. W. Büchler, "Colorectal cancer, " The Lancet, vol. 365, no. 9454, pp. 153-165, 2005.
2. F. di Fiore, F. Blanchard, F. Charbonnier et al., "Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, " British Journal of Cancer, vol. 96, no. 8, pp. 1166-1169, 2007.
3. A. Lièvre, J. B. Bachet, D. leCorre et al., "KRASmutation status is predictive of response to cetuximab therapy in colorectal cancer, " Cancer Research, vol. 66, no. 8, pp. 3992-3995, 2006.
4. R. G. Amado, M. Wolf, M. Peeters et al., "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, " Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626-1634, 2008.
5. European Medicine Agency, "Committee for medical products for human use, " Plenary Meeting Monthly Report, 2007.
6. S. Benvenuti, A. Sartore-Bianchi, F. di Nicolantonio et al., "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies, " Cancer Research, vol. 67, no. 6, pp. 2643-2648, 2007.
7. F. Sclafani, G. Gullo, K. Sheahan, and J. Crown, "BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications, " Critical Reviews in Oncology/Hematology, vol. 87, no. 1, pp. 55-68, 2012.
8. A. Lièvre, H. Blons, and P. Laurent-Puig, "Oncogenicmutations as predictive factors in colorectal cancer, " Oncogene, vol. 29, no. 21, pp. 3033-3043, 2010.
9. E. Domingo, P. Laiho, M. Ollikainen et al., "BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing, " Journal ofMedical Genetics, vol. 41, no. 9, pp. 664-668, 2004.
10. D. Soulières, W. Greer, A. M. Magliocco et al., "KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies, " Current Oncology, vol. 17, no. S1, pp. S31-S40, 2010.
11. J.-C. Sabourin, A. Lamy, F. Le Pessot, R. Sesbouë, and T. Frébourg, "Pathologie moléculaire tumorale: à propos du génotypage de KRAS dans les carcinomes colorectaux, " Revue Francophone des Laboratoires, vol. 2010, no. 418, pp. 43-46, 2010.
12. V. Shankaran, D. J. Bentrem, M. F. Mulcahy, C. L. Bennett, and A. B. Benson III, "Economic implications of Kras testing in metastatic colorectal cancer (mCRC), " in Proceedings of theGastrointestinal Cancers Symposium, abstract 298, San Francisco, Calif, USA, January 2009.
13. D. Muirhead, P. Aoun, M. Powell, F. Juncker, and J. Mollerup, "Pathology economic model tool: a novel approach to workflow and budget cost analysis in an anatomic pathology laboratory, " Archives of Pathology and Laboratory Medicine, vol. 134, no. 8, pp. 1164-1169, 2010.
14. B. Liegl-Atzwanger, J. A. Fletcher, and C. D. M. Fletcher, "Gastrointestinal stromal tumors, " Virchows Archiv, vol. 456, no. 2, pp. 111-127, 2010.
15. O. Bouché and F. Penault-Llorca, "HER2 and gastric cancer: a novel therapeutic target for trastuzumab, " Bulletin du Cancer, vol. 97, no. 12, pp. 1429-1440, 2010.
16. J. S. Ross, "Update on HER2 testing for breast and upper gastrointestinal tract cancers, " Biomarkers in Medicine, vol. 5, no. 3, pp. 307-318, 2011.
17. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli, "Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy inmetastatic colorectal cancer, " Journal of the National Cancer Institute, vol. 101, no. 19, pp. 1308-1324, 2009.
18. M. Brevet, M. Arcila, and M. Ladanyi, "Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR, " Journal of Molecular Diagnostics, vol. 12, no. 2, pp. 169-176, 2010.
19. A. Hasanovic, D. Ang, A. L. Moreira, andM. F. Zakowski, "Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma, " Lung Cancer, vol. 77, no. 2, pp. 299-305, 2012.
20. O. Koperek and C. Kornauth, "Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma, "The American Journal of Surgical Pathology, vol. 36, no. 6, pp. 844-850, 2012.
21. J. Yu, S. Kane, J. Wu et al., "Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer, " Clinical Cancer Research, vol. 15, no. 9, pp. 3023-3028, 2009.
22. D. Capper, M. Preusser, A. Habel et al., "Assessment of BRAF V600E mutation status by immunohistochemistry with amutation-specific monoclonal antibody, " Acta Neuropathologica, vol. 122, no. 1, pp. 11-19, 2011.
23. K. Affolter, W. Samowitz, S. Tripp, and M. P. Bronner, "BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma, " Genes Chromosomes and Cancer, vol. 52, no. 8, pp. 748-752, 2013.
24. F. A. Sinicrope, T. C. Smyrk, D. Tougeron et al., "Mutationspecific antibody detects mutant BRAF600 protein expression in human colon carcinomas, " Cancer, vol. 119, no. 15, pp. 2765-2770, 2013.
25. D. Capper, A. Voigt, G. Bozukova et al., "BRAFV600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer, " International Journal of Cancer, vol. 133, no. 7, pp. 1624-1630, 2013.
26. E. Domingo, R. C. Niessen, C. Oliveira et al., "BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, " Oncogene, vol. 24, no. 24, pp. 3995-3998, 2005.
27. P. G. Gavin, L. H. Colangelo, D. Fumagalli et al., "Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value, " Clinical Cancer Research, vol. 18, no. 23, pp. 6531-6541, 2012.
28. W. de Roock, B. Claes, D. Bernasconi et al., "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, " The Lancet Oncology, vol. 11, no. 8, pp. 753-762, 2010.
29. Z.-X. Yuan, X.-Y. Wang, Q.-Y. Qin et al., "The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: ameta-analisis, " PLoS ONE, vol. 8, no. 6, Article IDe65995, 2013.
30. B. Higgins, K. D. Kolinsky, K. Schostack et al., "Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model, " Journal of Clinical Oncology, vol. 30, supplement 4, 2012, abstract 494.
31. M. Y. Al-Marrawi, B. S. Saroya, M. C. Brennan, Z. Yang, T. M. Dykes, and W. S. El-Deiry, "Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer, " Cancer Biology and Therapy, vol. 14, no. 8, pp. 703-710, 2013.
32. M. Gerlinger, A. J. Rowan, S. Horswell et al., "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, "The New England Journal ofMedicine, vol. 366, no. 8, pp. 883-892, 2012.